These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 23074941)
1. [Silodosin treatment of patients with prostatic adenoma]. Govorov AV; Pushkar' DIu Urologiia; 2012; (3):71-4. PubMed ID: 23074941 [No Abstract] [Full Text] [Related]
2. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new? Morgia G Eur Urol; 2011 Mar; 59(3):353-5; discussion 355. PubMed ID: 21130562 [No Abstract] [Full Text] [Related]
3. [Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia]. Ogawa T; Uemura H; Sano F; Hoshino K; Kita K; Hayashi N; Kagota M; Murakami T; Makiyama K; Miyoshii Y; Nakaigawa N; Yao M; Shimura H; Furuhata A; Fujikawa N; Shioi K; Ueki T; Hara Y; Saitou K; Kawakami S; Satomi Y; Hattori Y; Teranishi J; Kondo K; Kishida T; Saito K; Noguchi K; Fuji H; Yamaguchi T; Kinoshita Y; Nomura S; Yoshida M; Sakai N; Terao H; Matsumoto T; Umemoto S; Ogo Y; Kobayashi K; Noguchi S; Asakura T; Kohdaira T; Iguchi K; Izumi K; Hirano M; Kanno H; Takahashi T; Nukui F; Mokuo Y; Muraoka K; Osada Y; Funahashi M; Kitami K; Sugiura S; Ohta J; Miura T; Ishibashi Y; Masuda M; Komiya A; Suwa Y; Hashiba T; Mitaka K; Kobayashi M; Ohsaka K; Futoshi T; Tsuchiya T; Iwasaki A; Yamashita Y; Matsuzaki J; Kubota Y Hinyokika Kiyo; 2008 Dec; 54(12):757-64. PubMed ID: 19174997 [TBL] [Abstract][Full Text] [Related]
4. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms. Yoshida M; Kudoh J; Homma Y; Kawabe K Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148 [TBL] [Abstract][Full Text] [Related]
5. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Schilit S; Benzeroual KE Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995 [TBL] [Abstract][Full Text] [Related]
6. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G Urology; 2009 Dec; 74(6):1318-22. PubMed ID: 19815265 [TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality]. Kogan MI; Kireev AIu Urologiia; 2013; (6):58-60. PubMed ID: 24649766 [TBL] [Abstract][Full Text] [Related]
8. Silodosin (Rapaflo) for benign prostatic hyperplasia. Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568 [TBL] [Abstract][Full Text] [Related]
9. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791 [TBL] [Abstract][Full Text] [Related]
10. Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G J Urol; 2013 Jan; 189(1 Suppl):S122-8. PubMed ID: 23234617 [TBL] [Abstract][Full Text] [Related]
11. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887 [TBL] [Abstract][Full Text] [Related]
12. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Kawabe K; Yoshida M; Homma Y; BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121 [TBL] [Abstract][Full Text] [Related]
14. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954 [TBL] [Abstract][Full Text] [Related]
16. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Lepor H; Hill LA Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397 [TBL] [Abstract][Full Text] [Related]
17. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Homma Y; Kawabe K; Takeda M; Yoshida M Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263 [TBL] [Abstract][Full Text] [Related]
18. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E; Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344 [TBL] [Abstract][Full Text] [Related]
19. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]